Long-term treatment with erlotinib for EGFR wild-type non-small cell lung cancer: A case report

Case Reports in Oncology

Volumn 6, Issue 1, 2013, Pages 189-196

  Polychronidou, Genovefa ^a   Papakotoulas, Pavlos ^a  

^a THEAGENIO CANCER HOSPITAL   (Greece)

Author keywords

Epidermal growth factor receptor; Erlotinib; Gefitinib; Long term maintenance treatment; Tyrosine kinase inhibitors; Wild type non small cell lung cancer

Indexed keywords

ANTIBIOTIC AGENT; CARBOPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIRUBICIN; ERLOTINIB; ETOPOSIDE; GEFITINIB; GEMCITABINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BONE SCINTISCANNING; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DRUG ACTIVITY; DRUG EFFICACY; GENE MUTATION; GREECE; HUMAN; HUMAN TISSUE; LONG TERM CARE; MAINTENANCE THERAPY; MALE; MEDIASTINUM MASS; NON SMALL CELL LUNG CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RASH; SMOKING; THORAX RADIOGRAPHY; TREATMENT DURATION; WILD TYPE;

EID: 84877938481     PISSN: None     EISSN: 16626575     Source Type: Journal    
DOI: 10.1159/000350680     Document Type: Article

References (22)

1. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabárbara P, Seymour L; National Cancer Institute of Canada Clinical Trials Group: Erlotinib in previously treated nonsmall-cell lung cancer. N Engl J Med 2005;353:123-132.
2. Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczésna A, Juhász E, Esteban E, Molinier O, Brugger W, Melezínek I, Klingelschmitt G, Klughammer B, Giaccone G; SATURN investigators: Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010;11:521-529.
3. TarcevaTM Summary of Product Characteristics, 2012. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000618/human-med-001077.jsp&mid=WC0b01ac058001d124 (accessed January 2013).
4. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L, You C: Erlotinib versus chemotherapy as firstline treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12:735-742.
5. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive nonsmall-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239-246.
6. GefitinibTM Summary of Product Characteristics, 2012. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001016/human-med-000857.jsp&mid=WC0b01ac058001d125&murl=menus/medicines/medicines.jsp (accessed January 2013).
7. Zhu CQ, da Cunha Santos G, Ding K, Sakurada A, Cutz JC, Liu N, Zhang T, Marrano P, Whitehead M, Squire JA, Kamel-Reid S, Seymour L, Shepherd FA, Tsao MS; National Cancer Institute of Canada Clinical Trials Group Study BR.21: Role of K-RAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008;26:4268-4275.
8. Brugger W, Triller N, Blasinska-Morawiec M, Curescu S, Sakalauskas R, Manikhas GM, Mazieres J, Whittom R, Ward C, Mayne K, Trunzer K, Cappuzzo F: Prospective molecular marker analyses of EGFR and K-RAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. J Clin Oncol 2011;29:4113-4120.
9. Kobayashi T, Koizumi T, Agatsuma T, Yasuo M, Tsushima K, Kubo K, Eda S, Kuraishi H, Koyama S, Hachiya T, Ohura N: A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 2012;69:1241-1246.
10. Ciuleanu T, Stelmakh L, Cicenas S, Miliauskas S, Grigorescu AC, Hillenbach C, Johannsdottir HK, Klughammer B, Gonzalez EE: Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, openlabel, phase 3 study. Lancet Oncol 2012;13:300-308.
11. Martelli O, Garassino MC, Longo F, Moscetti L, Bettini A, Tomirotti M, Pavese I, Alabiso O, Sarobba G, Palmeri L, Bertolini A, Vattemi E, Ferrari V, Ardizzoia A, Mancuso A, Pellegrino A, Cavanna L, Contu A, Del Bene G, Labianca R, Fabbri MA, Bareggi C, Bonomi L, Veronese S, Lauricella C, Broggini M, Marabese M, Ganzinelli M, Rulli E, Copreni E, Floriani I, Marsoni S, Farina G, Scanni A: TAILOR: phase III trial comparing erlotinib versus docetaxel as second-line treatment of advanced non-small cell lung cancer (NSCLC) patients with wild type EGFR (wt) (abstract 4). J Exp Clin Oncol 2012;13:S2.
12. Peters S, Adjei AA, Gridelli C, Reck M, Kerr K, Felip E; ESMO Guidelines Working Group: Metastatic nonsmall-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23:vii56-vii64.
13. Becker A, van Wijk A, Smit EF, Postmus PE: Side-effects of long-term administration of erlotinib in patients with non-small cell lung cancer. J Thorac Oncol 2010;5:1477-1480.
14. Wacker B, Nagrani T, Weinberg J, Witt K, Clark G, Cagnoni PJ: Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 2007;13:3913-3921.
15. Petrelli F, Borgonovo K, Cabiddu M, Lonati V, Barni S: Relationship between skin rash and outcome in nonsmall-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based metaanalysis of 24 trials. Lung Cancer 2012;78:8-15.
16. Kawaguchi T, Takada M, Kubo A, Matsumura A, Fukai S, Tamura A, Saito R, Maruyama Y, Kawahara M, Ignatius Ou SH: Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC. J Thorac Oncol 2010;5:620-630.
17. Giroux Leprieur E, Lavole A, Ruppert AM, Gounant V, Wislez M, Cadranel J, Milleron B: Factors associated with long-term survival of patients with advanced non-small cell lung cancer. Respirology 2012;17:134-142.
18. Schumann C, Heigener D, Dittrich I, Abenhardt W, Dederke B, Duell T, Matzdorff A, Raack BW, Steins M, Schneider CP: Long term benefit from erlotinib treatment is independent of prognostic factors and therapeutic response (abstract 9146). Eur J Cancer 2009;7:1.
19. Kaira K, Takahashi T, Murakami H, Tsuya A, Nakamura Y, Naito T, Endo M, Yamamoto N: Long-term survivors of more than 5 years in advanced non-small cell lung cancer. Lung Cancer 2010;67:120-123.
20. Gottschling S, Herpel E, Eberhardt WE, Heigener DF, Fischer JR, Köhne CH, Kortsik C, Kuhnt T, Muley T, Meister M, Bischoff HG, Klein P, Moldenhauer I, Schnabel PA, Thomas M, Penzel R: The gefitinib long-term responder (LTR)-a cancer stem-like cell story? Insights from molecular analyses of German long-term responders treated in the IRESSA expanded access program (EAP). Lung Cancer 2012;77:183-191.
21. Nakatomi K, Soda H, Kitazaki T, Nakano H, Uchida K, Urabe S, Nakamura Y, Hayashi T, Tsukamoto K, Kohno S: Long-term survival in three patients with metastatic non-small cell lung cancer treated with gefitinib. Lung Cancer 2006;52:253-255.
22. Reck M, Gatzemeier U: Benefit in lung function improvement and side-effect profile of long-term responders: an analysis of 14 NSCLC patients treated for at least 9 months with gefitinib. Lung Cancer 2005;50:107-114.